Trial Profile
A Pilot Study of Daratumumab (CD38 Antagonist) in Patients With Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 31 Oct 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Bladder cancer; Renal cell carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Oct 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 26 Oct 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 18 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.